To include your compound in the COVID-19 Resource Center, submit it here.

EC approves Symtuza for HIV-1, Janssen submits NDA to FDA

Johnson & Johnson (NYSE:JNJ) said in September its Janssen Research & Development LLC unit submitted an NDA to

Read the full 181 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE